Inhibition of hiv infection of H9 cells by chlorpromazine derivatives

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 15, Issue 1, 1997, Pages 16-20

  Hewlett, Indira ^a   Lee, Sherwin ^a   Molnar, Jozsef ^b   Foldeak, Sandor ^b   Pine, P Scott ^a   Weaver, James L ^a   Aszalos, Adorjan ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Anti Leu3a binding; Dioxo chlorpromazine; HIV infectivity; Syncytia formation

Indexed keywords

7,8 DIOXOCHLORPROMAZINE; CHLORPROMAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; SYNCYTIUM; VIRUS INHIBITION; VIRUS PATHOGENESIS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0030753123     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199705010-00003     Document Type: Article

References (16)

1. Szekely Z. A new approach for an HIV docking-inhibitor drug design on the basis of the dual recognition/binding hypothesis between the CD4 receptor and the envelop glycoprotein of the HIV. J Mol Struct 1995;334:93-100.
2. Ptaszek LM, Vijayakumar S, Ravishanker G, Beveridge DL. Molecular dynamics studies of the CD4 protein. Biopolymers 1994; 34:1145-53.
3. Laski LA, Nakamura G, Smith DH, et al. Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with CD4 receptor. Cell 1987;50:975-85.
4. Balzarini J, Mitsuya H, De Clercq E, Broder S. Aurin tricarboxylic acid and Evans Blue represent two different classes of anionic compounds which selectively inhibit the cytopathogenicity of human T-cell lymphotropic virus type 111/lymphadenopathy-associated virus. Biochem Biophys Res Commun 1986;136:64-71.
5. Weaver JL, Pine PS, Anand R, Bell S, Aszalos A. Inhibition of the binding of HIV rgp120 to CD4 by dyes. Antiviral Chem Chemother 1992;3:147-51.
6. Baba M, Pauwels R, Balzarini J, Arnout J, Desmyter J, De Clercq E. Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proc Natl Acad Sci U S A 1988;85:6132-6.
7. Molnar J, Foldeak S, Nakamura MJ, Gaizer F, Gutmann F. The influence of charge transfer formation on the antibacterial activity of some tricyclic drugs. Xenobiotica 1991;21:309-16.
8. Lee FGH, Suzuki KI, Dickson Donald E, Manian AA. Synthesis of 7,8-dihydroxy-chlorpromazine and analogs. J Heterocyclic Chem 1972;9:387-391.
9. Zirnis A, Suzuki KI, Daly JW, Manian AA. 7,8-Dioxochlorpromazine synthesis and properties. J Heterocyclic Chem 1975;12:239-42.
10. Weaver JL, Gergely P, Pine PS, Patzer E, Aszalos A. Polyionic compounds selectively alter availability of CD4 receptors for HIV coat protein rgp120. AIDS Res Hum Retroviruses 1990;6:1125-30.
11. Jonak ZL, Clark RK, Matour D, et al. A human lymphoid recombinant cell line with functional human immunodeficiency virus type 1 envelope. AIDS Res Hum Retroviruses 1993;9:23-32.
12. Dhawan S, Heredia A, Lal RB, Wahl LM, Epstein JS, Hewlett IK, Interferon-gamma induces resistance in primary monocytes against human immunodeficiency virus type-1 infection. Biochem Biophys Res Commun 1994;201:756-61.
13. Szekely Z, Perczel A, Penke B, Molnar J. A new method for the interpretation of dynamics trajectories in the conformational analysis of HIV receptor mutants. J Mol Struct 1993;286:165-82.
14. Ryu SE, Kwong PD, Trunek A, et al. Crystal structure of an HIV-binding recombinant fragment of human CD4. Nature 1990; 348:419-26.
15. Szabo G Jr, Pine PS, Weaver JL, Rao PE, Aszalos A. CD4 changes conformation upon ligand binding. J Immunol 1992;149:3596-3609.
16. Gallo RC. Human retroviruses in the second decade: a personal perspective. Nat Med 1995;1:753-9.